Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

New study published in Journal of Electromagnetic Biology and Medicine provides additional validation for Company’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Please provide your email address to receive an email when new articles are posted on . Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for ...

Dordaviprone has been granted Priority Review by the FDA for recurrent H3 K27M-mutant diffuse glioma, with a target action date of August 18. The drug has received Rare Pediatric Disease, Fast-Track, ...

DUBLIN, Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical ...

Moleculin Biotech Inc. (NASDAQ:MBRX) shares fell 9.1% in premarket trading on Wednesday after the company disclosed results from a Phase 1 clinical study evaluating its drug candidate WP1066 in ...